- Home
- TJGC vs BYSI Comparison
TJGC vs BYSI Comparison
Compare TJGC & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJGC | BYSI |
|---|---|---|
| Founded | 2022 | 2010 |
| Country | Hong Kong | United States |
| Employees | 19 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9M | 58.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | TJGC | BYSI |
|---|---|---|
| Price | $6.11 | $1.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 23.4K |
| Earning Date | 08-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $1.18 |
| 52 Week High | $2.18 | $3.44 |
Technical Indicators
Market Signals| Indicator | TJGC | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 93.51 | 59.94 |
| Support Level | $0.80 | $1.69 |
| Resistance Level | N/A | $1.85 |
| Average True Range (ATR) | 0.49 | 0.18 |
| MACD | 0.31 | 0.04 |
| Stochastic Oscillator | 90.14 | 91.60 |
Price Performance
Historical ComparisonAbout TJGC TJGC Group Limited Ordinary Shares
TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.